What is the recommended management for a Thyroid Imaging Reporting and Data System (TI-RADS) 2 thyroid nodule in pregnancy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of TI-RADS 2 Thyroid Nodules in Pregnancy

A TI-RADS 2 thyroid nodule in pregnancy requires no intervention beyond routine observation, as these nodules are benign by definition and do not require fine-needle aspiration, thyroid function testing, or any specific monitoring during pregnancy.

Understanding TI-RADS 2 Classification

  • TI-RADS 2 nodules are definitionally benign lesions that include spongiform nodules or nodules composed of multiple microcystic components, which carry essentially no malignancy risk 1
  • These nodules do not meet criteria for biopsy at any size, unlike higher-risk categories 2, 1

Recommended Management Approach

No Active Intervention Required

  • No fine-needle aspiration is indicated for TI-RADS 2 nodules regardless of size, as the malignancy risk is negligible 2, 1
  • Thyroid function testing (TSH) is not specifically required for TI-RADS 2 nodules unless the patient has symptoms of thyroid dysfunction or other clinical indications 3
  • No ultrasound surveillance during pregnancy is necessary for confirmed TI-RADS 2 nodules 1

Pregnancy-Specific Considerations

  • The approach to thyroid nodules in pregnancy should mirror that for non-pregnant patients, with evaluation focused on identifying potentially malignant lesions 4, 5
  • All thyroid nodules should be evaluated during pregnancy according to ACOG guidelines, but this refers to determining their risk category, not performing invasive procedures on benign lesions 3
  • Thyroid nodules may increase in size during pregnancy (particularly in the third trimester), but this physiologic change does not alter management of definitionally benign TI-RADS 2 nodules 6

Important Clinical Caveats

Ensure Accurate Classification

  • Verify that the nodule is truly TI-RADS 2 and not misclassified; if there is any uncertainty about the classification or if suspicious features are present (solid hypoechoic appearance, irregular margins, microcalcifications, taller-than-wide shape), the nodule should be reclassified to the appropriate higher-risk category 1, 7
  • If the nodule was classified as TI-RADS 2 but shows concerning features on review, it requires re-evaluation using proper TI-RADS criteria 2, 1

When to Reconsider

  • If the nodule demonstrates rapid growth, develops new suspicious ultrasound features, or is associated with palpable cervical lymphadenopathy, re-evaluation with possible reclassification and FNA may be warranted even during pregnancy 8
  • New symptoms such as compressive symptoms, hoarseness, or dysphagia should prompt clinical reassessment 5

Postpartum Management

  • No routine postpartum follow-up is required for confirmed TI-RADS 2 nodules unless new clinical concerns arise 1
  • If thyroid function abnormalities develop postpartum (which can occur with postpartum thyroiditis), TSH and free T4 should be measured, but this is unrelated to the benign nodule itself 3

References

Guideline

TIRADS Guideline Summary

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Thyroid Nodules and Pulmonary Findings

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Management of thyroid nodules in pregnancy.

Archives of internal medicine, 1996

Research

Thyroid Nodules and Thyroid Cancer in the Pregnant Woman.

Endocrinology and metabolism clinics of North America, 2019

Research

Thyroid Nodules: Advances in Evaluation and Management.

American family physician, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.